Categories AlphaGraphs, Earnings, Health Care
A visual dashboard of Amgen’s (AMGN) Q1 2020 earnings results
Amgen’s (NASDAQ: AMGN) top and bottom line in the first quarter of 2020 beat analysts’ estimates. The biotech firm’s adjusted earnings per share surged 17% to $4.17, driven by increased revenues and fewer weighted-average shares outstanding. Revenue rose 11% annually to $6.2 billion. AMGN stock was trading up about 1% during the extended-hours.
GAAP earnings per share decreased 3% to $3.07 in the first quarter. Product sales increased 12% globally, driven by volume growth across a number of Amgen’s newer products.
Amgen reaffirmed its 2020 revenue guidance of $25.0 billion to-$25.6 billion. GAAP EPS guidance was revised to a range of $10.65 to $11.45 and the company maintained the non-GAAP EPS outlook of $14.85-$15.60.
Amgen announced that Otezla, an oral treatment approved in more than 50 countries for inflammatory diseases such as psoriasis and psoriatic arthritis, will be investigated as a potential immunomodulatory treatment in adult patients with COVID-19 in upcoming platform trials.
Most Popular
PNC Earnings: A snapshot of PNC Financial Services’ Q4 2025 results
PNC Financial Services Group, Inc. (NYSE: PNC) on Friday reported higher revenue and net income for the fourth quarter of fiscal 2025. The numbers also beat analysts' estimates. Total revenues
Earnings Preview: Intuitive Surgical (ISRG) looks poised for a strong Q4
Intuitive Surgical, Inc. (NASDAQ: ISRG) is a pioneer in robotic-assisted surgical technology, developing advanced systems that enable healthcare professionals to perform minimally invasive procedures with greater precision and efficiency. Having
What to expect when Alaska Air Group (ALK) reports Q4 2025 earnings results
Shares of Alaska Air Group (NYSE: ALK) gained 3% on Thursday. The stock has dropped 26% in the past 12 months. The airline is scheduled to publish its earnings results
